IDH1 and glioma: In light of the inconsistent clinical outcomes with IDH inhibitors in high-grade gliomas so far [140, 141], we and others have proposed that “instead of shutting down mutant IDH enzymes, exploiting the selective vulnerabilities caused by them might be another attractive and promising strategy” [142].